Turn Therapeutics (NASDAQ:TTRX) Upgraded to Hold at Zacks Research

Turn Therapeutics (NASDAQ:TTRX) was upgraded by stock analysts at Zacks Research to a “hold” rating in a report released on Tuesday,Zacks.com reports.

TTRX has been the topic of several other reports. Weiss Ratings raised Turn Therapeutics from a “sell (e)” rating to a “sell (d-)” rating in a research report on Monday, July 13th. Wall Street Zen raised Turn Therapeutics to a “hold” rating in a report on Saturday, July 18th. D. Boral Capital restated a “buy” rating and issued a $8.00 price target on shares of Turn Therapeutics in a research note on Tuesday, March 24th. Finally, LADENBURG THALM/SH SH raised Turn Therapeutics to a “strong-buy” rating in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Turn Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.00.

Turn Therapeutics Trading Down 5.5%

Shares of NASDAQ TTRX opened at $9.62 on Tuesday. The firm’s 50 day moving average price is $6.70 and its 200-day moving average price is $4.81. The company has a market cap of $286.58 million and a PE ratio of -50.63. Turn Therapeutics has a 52-week low of $2.57 and a 52-week high of $26.50. The company has a debt-to-equity ratio of 0.97, a quick ratio of 2.23 and a current ratio of 2.23.

Turn Therapeutics (NASDAQ:TTRX) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.03) EPS for the quarter. On average, equities research analysts expect that Turn Therapeutics will post -0.09 EPS for the current fiscal year.

Institutional Investors Weigh In On Turn Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. XTX Topco Ltd bought a new stake in Turn Therapeutics in the 4th quarter worth approximately $99,000. Millennium Management LLC purchased a new stake in Turn Therapeutics during the 4th quarter valued at $377,000. Jane Street Group LLC bought a new position in shares of Turn Therapeutics during the 4th quarter valued at $68,000. Brown Brothers Harriman & Co. bought a new position in shares of Turn Therapeutics during the 4th quarter valued at $93,000. Finally, Geode Capital Management LLC bought a new position in shares of Turn Therapeutics during the 4th quarter valued at $68,000.

About Turn Therapeutics

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.